首页> 外文期刊>Journal of Asthma and Allergy >Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR): physician beliefs and practices about diagnosis, assessment, and treatment of coexistent disease
【24h】

Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR): physician beliefs and practices about diagnosis, assessment, and treatment of coexistent disease

机译:亚太地区哮喘和过敏性鼻炎医师调查(ASPAIR):医师关于共存疾病的诊断,评估和治疗的信念和实践

获取原文
           

摘要

Background: Asthma and allergic rhinitis (AR) frequently coexist, and having both asthma and AR is associated with uncontrolled asthma and a heavier disease burden. The Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR) aimed to assess physicians’ perceptions and their management practices for patients with coexistent disease. Materials and methods: A total of 1,204 general physicians and pediatricians from six countries in Asia, who routinely treat asthma patients, were interviewed in-person. Physicians were questioned about their attitudes and beliefs of coexistent asthma-AR, how they diagnose and treat patients, and their knowledge of international guideline recommendations. Results: Physicians reported that 45% of their patients with asthma have coexistent AR and 37% of their patients with AR have coexistent asthma. Most physicians (77%) agreed that coexistent asthma-AR is a genuine condition and that patients suffer worse symptoms with both the conditions vs one alone (86%). Although nearly all agreed that both asthma and AR should be treated (91%) and that intranasal (INS) and inhaled corticosteroids (ICS) could be given concurrently to these patients, 40% also thought that treating both conditions effectively at the same time is difficult, and approximately a quarter believed that corticosteroid therapy should be delayed in children for both asthma and AR. While there was universal recognition and acceptance that guidelines provide sufficient information for treating uncontrolled coexistent disease (≥80% physicians in all countries), physicians revealed that 41% of their asthma patients are treated with short-acting rescue medications alone, and only 47% responded that treatment with concurrent INS and ICS, as recommended in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, was their preferred treatment for coexistent disease. Conclusion: The ASPAIR survey demonstrates a widespread acceptance of coexistent asthma-AR, and the associated burden, but highlights the need for increased healthcare practitioner communication and awareness to improve appropriate treatment and management of these coexistent conditions.
机译:背景:哮喘和变应性鼻炎(AR)经常并存,哮喘和AR并发与哮喘的控制和疾病负担加重有关。亚太地区哮喘和过敏性鼻炎医师调查(ASPAIR)旨在评估医师对共存疾病患者的看法及其管理实践。材料和方法:亲自采访了来自亚洲六个国家的1,204名常规医师和儿科医生,他们常规治疗哮喘患者。向医师询问有关他们共存哮喘-AR的态度和信念,如何诊断和治疗患者以及对国际指南建议的了解。结果:医师报告说,他们的哮喘患者中有45%患有AR并存,而37%的AR患者中有哮喘并存。大多数医生(77%)认为并存的哮喘-AR是一种真正的疾病,与这两种疾病相比,两种情况的患者均出现更严重的症状(86%)。尽管几乎所有人都同意应同时治疗哮喘和AR(91%),并且可以同时向这些患者给予鼻内(INS)和吸入糖皮质激素(ICS),但40%的人还认为同时有效地治疗这两种疾病是困难,大约四分之一的人认为对于哮喘和AR患儿应延迟皮质类固醇治疗。尽管人们普遍认可并接受指南为治疗无法控制的并存疾病提供了足够的信息(在所有国家中≥80%的医生),但医生透露他们的哮喘患者中有41%仅接受短效急救药物治疗,只有47%回应说,按照变应性鼻炎及其对哮喘的影响(ARIA)指南中的建议,并发INS和ICS治疗是他们共存疾病的首选治疗方法。结论:ASPAIR调查表明,共存哮喘-AR及其相关负担已被广泛接受,但强调需要加强医疗从业人员的沟通和认识,以改善对这些共存病的适当治疗和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号